{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:04:59Z","timestamp":1787025899849,"version":"build-2736575974"},"reference-count":13,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T00:00:00Z","timestamp":1510617600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2018,2,17]]},"abstract":"\n Background:<\/jats:title>\n The independent contribution of levodopa exposure and Parkinson\u2019s disease (PD) to the risk of polyneuropathy is not established.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n This study investigated whether patients with newly diagnosed PD without previous exposure to antiparkinsonian drugs have higher prevalence of polyneuropathy than the general population.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Using the UK General Practice Research Database, presence of polyneuropathy in the previous 3 years was assessed.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Of 5089 PD patients and 19,897 controls, polyneuropathy was confirmed in 15 PD patients (0.29% ) and 24 controls (0.12% ). Polyneuropathy prevalence was 2.4-fold higher in PD patients than controls.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n In this observational study, PD patients had a higher prevalence of preexisting polyneuropathy that cannot be explained by adverse effects of antiparkinsonian drugs.<\/jats:p>\n <\/jats:sec>","DOI":"10.3233\/jpd-161057","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T11:24:07Z","timestamp":1510658647000},"page":"141-144","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Increased Prevalence of Polyneuropathy in\u00a0Parkinson\u2019s Disease Patients: An\u00a0Observational Study"],"prefix":"10.1177","volume":"8","author":[{"given":"Christian","family":"Conradt","sequence":"first","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianlin","family":"Guo","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Miclea","sequence":"additional","affiliation":[{"name":"Abbott Laboratories, EDP Global Pharmacovigilance, Hannover,\r Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nisslein","sequence":"additional","affiliation":[{"name":"Abbott Laboratories, EDP Global Pharmacovigilance, Hannover,\r Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim","family":"Ismail","sequence":"additional","affiliation":[{"name":"PB Consulting Network, Oberpfalz,\r Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krai","family":"Chatamra","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Andersohn","sequence":"additional","affiliation":[{"name":"Institute for Social Medicine, Epidemiology, and Health\r Economics, Charit\u00e9 University Medical Center, Frank Andersohn\r Consulting and Research Services, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"ref001","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823a0ee4"},{"key":"ref002","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7079-8"},{"key":"ref003","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22137"},{"key":"ref004","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22021"},{"key":"ref005","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22330"},{"key":"ref006","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062222"},{"key":"ref007","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp10X483562"},{"issue":"7","key":"ref008","first-page":"14","volume":"251","author":"Hernan MA","year":"2004","journal-title":"J Neurol"},{"key":"ref009","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22616"},{"key":"ref010","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn102"},{"key":"ref011","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20113"},{"key":"ref012","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(02)00114-1"},{"key":"ref013","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2016.04.033"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-161057","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JPD-161057","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JPD-161057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:45:46Z","timestamp":1777610746000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JPD-161057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2,17]]}},"alternative-id":["10.3233\/JPD-161057"],"URL":"https:\/\/doi.org\/10.3233\/jpd-161057","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]}}}